ALZAMEND NEURO, INC. Earnings Per Share (Basic)
ALZAMEND NEURO, INC. (ALZN) reported Earnings Per Share (Basic) of -$0.68 per share for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-09-10
- ALZAMEND NEURO, INC. earnings per share, basic for the quarter ending 2026-07-31 was -$0.68.
- ALZAMEND NEURO, INC. earnings per share, basic for the quarter ending 2026-04-30 was -$0.72.
- ALZAMEND NEURO, INC. earnings per share, basic for the quarter ending 2026-01-31 was -$0.58.
- ALZAMEND NEURO, INC. earnings per share, basic for the quarter ending 2025-10-31 was -$0.30.
- ALZAMEND NEURO, INC. earnings per share, basic for fiscal 2026 was -$2.63.
- ALZAMEND NEURO, INC. earnings per share, basic for fiscal 2025 was -$11.32.
- ALZAMEND NEURO, INC. earnings per share, basic for fiscal 2024 was -$132.33.
- ALZAMEND NEURO, INC. earnings per share, basic for fiscal 2023 was -$22.89.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-07-31 | -$0.68 10-Q · filed 2026-09-10 | $0.03 derived: net income ÷ weighted average shares · filed 2026-09-10 | -$0.51 derived: net income ÷ weighted average shares · filed 2026-09-10 | -$0.78 derived: net income ÷ weighted average shares · filed 2026-09-10 | ||||
| 2026-04-30 | -$0.72 derived: net income ÷ weighted average shares · filed 2026-07-22 | -$1.30 derived: net income ÷ weighted average shares · filed 2026-07-22 | -$1.63 derived: net income ÷ weighted average shares · filed 2026-07-22 | -$2.63 10-K · filed 2026-07-22 | ||||
| 2026-01-31 | -$0.58 10-Q · filed 2026-03-11 | -$0.89 derived: net income ÷ weighted average shares · filed 2026-03-11 | -$1.89 10-Q · filed 2026-03-11 | -$3.02 derived: net income ÷ weighted average shares · filed 2026-09-10 | ||||
| 2025-10-31 | -$0.30 10-Q · filed 2025-12-09 | -$1.33 10-Q · filed 2025-12-09 | -$2.59 derived: net income ÷ weighted average shares · filed 2026-09-10 | -$3.77 derived: net income ÷ weighted average shares · filed 2026-09-10 | ||||
| 2025-07-31 | -$1.28 10-Q · filed 2026-09-10 | -$3.08 derived: net income ÷ weighted average shares · filed 2026-09-10 | -$4.74 derived: net income ÷ weighted average shares · filed 2026-09-10 | -$7.15 derived: net income ÷ weighted average shares · filed 2026-09-10 | ||||
| 2025-04-30 | -$2.30 derived: net income ÷ weighted average shares · filed 2026-07-22 | -$4.09 derived: net income ÷ weighted average shares · filed 2026-07-22 | -$7.21 derived: net income ÷ weighted average shares · filed 2026-07-22 | -$11.32 10-K · filed 2026-07-22 | ||||
| 2025-01-31 | -$1.75 10-Q · filed 2026-03-11 | -$0.19 10-Q · filed 2025-03-10 | -$4.96 derived: net income ÷ weighted average shares · filed 2026-03-11 | -$9.54 10-Q · filed 2026-03-11 | -$1.03 10-Q · filed 2025-03-10 | |||
| 2024-10-31 | -$3.61 10-Q · filed 2025-12-09 | -$0.40 10-Q · filed 2024-12-11 | -$9.98 10-Q · filed 2025-12-09 | -$1.11 10-Q · filed 2024-12-11 | ||||
| 2024-07-31 | -$11.42 10-Q · filed 2025-09-10 | -$1.25 10-Q · filed 2024-09-11 | ||||||
| 2024-04-30 | -$132.33 10-K · filed 2025-07-22 | -$14.70 10-K · filed 2024-07-30 | ||||||
| 2024-01-31 | -$3.77 10-Q · filed 2025-03-10 | -$0.38 10-Q · filed 2024-03-25 | -$13.52 10-Q · filed 2025-03-10 | -$1.35 10-Q · filed 2024-03-25 | ||||
| 2023-10-31 | -$4.43 10-Q · filed 2024-12-11 | -$0.44 10-Q · filed 2023-12-15 | -$9.80 10-Q · filed 2024-12-11 | -$0.98 10-Q · filed 2023-12-15 | ||||
| 2023-07-31 | -$5.38 10-Q · filed 2024-09-11 | -$0.04 10-Q · filed 2023-09-13 | ||||||
| 2023-04-30 | -$22.89 10-K · filed 2024-07-30 | -$0.15 10-K · filed 2023-07-27 | ||||||
| 2023-01-31 | -$0.83 10-Q · filed 2024-03-25 | -$0.06 10-Q · filed 2023-03-15 | -$1.78 10-Q · filed 2024-03-25 | -$0.12 10-Q · filed 2023-03-15 | ||||
| 2022-10-31 | -$0.48 10-Q · filed 2023-12-15 | -$0.03 10-Q · filed 2022-12-12 | -$0.95 10-Q · filed 2023-12-15 | -$0.06 10-Q · filed 2022-12-12 | ||||
| 2022-07-31 | -$0.03 10-Q · filed 2023-09-13 | |||||||
| 2022-04-30 | -$0.14 10-K · filed 2023-07-27 | |||||||
| 2022-01-31 | -$0.03 10-Q · filed 2023-03-15 | -$0.09 10-Q · filed 2023-03-15 | ||||||
| 2021-10-31 | -$0.04 10-Q · filed 2022-12-12 | -$0.07 10-Q · filed 2022-12-12 | ||||||
| 2021-07-31 | -$0.03 10-Q · filed 2022-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |